<DOC>
	<DOCNO>NCT02215499</DOCNO>
	<brief_summary>This study conduct evaluate safety , tolerability , blood distribution effectiveness single ascend dos JZP-386 compare dos XyremÂ® placebo .</brief_summary>
	<brief_title>A Phase 1 , Single Dose Study JZP-386 Evaluate Safety , Pharmacokinetics Pharmacodynamics</brief_title>
	<detailed_description>This Phase 1 , single center , single-ascending dose , sequential , randomize , crossover study . Following Screening period 21 day , eligible subject randomize different dosing sequence , approximately 4 subject allocate dose sequence . The total in-clinic duration subject 24 day ( include admission day prior first dose period ) .</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Sodium Oxybate</mesh_term>
	<criteria>Healthy male female volunteer subject , 18 50 year age , inclusive . Clinically significant history unstable medical abnormality . Inability cooperate study procedure . Female subject positive pregnancy test result , nurse lactating . Participation investigational drug trial within 90 day prior screen . A history prescription drug abuse , illicit drug know drug dependence within last 5 year prior screen . Use prescription medication within 14 day prior dose . A history alcohol abuse dependence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>JZP-386 , Xyrem , sodium oxybate</keyword>
</DOC>